These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11751480)

  • 21. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
    O'Dwyer PJ; Laub PB; DeMaria D; Qian M; Reilly D; Giantonio B; Johnston AL; Wu EY; Bauman L; Clendeninn NJ; Gallo JM
    Clin Cancer Res; 1996 Oct; 2(10):1685-92. PubMed ID: 9816117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
    Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O; Hubert A; Gabizon AA
    Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
    Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
    Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
    Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
    Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.
    Hao D; Hammond LA; Eckhardt SG; Patnaik A; Takimoto CH; Schwartz GH; Goetz AD; Tolcher AW; McCreery HA; Mamun K; Williams JI; Holroyd KJ; Rowinsky EK
    Clin Cancer Res; 2003 Jul; 9(7):2465-71. PubMed ID: 12855619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
    Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
    Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
    J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
    Eskens FA; Awada A; Cutler DL; de Jonge MJ; Luyten GP; Faber MN; Statkevich P; Sparreboom A; Verweij J; Hanauske AR; Piccart M;
    J Clin Oncol; 2001 Feb; 19(4):1167-75. PubMed ID: 11181683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
    Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
    Weiss GR; Kuhn JG; Rizzo J; Smith LS; Rodriguez GI; Eckardt JR; Burris HA; Fields S; VanDenBerg K; von Hoff DD
    Cancer Chemother Pharmacol; 1995; 35(5):397-402. PubMed ID: 7850921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
    J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.